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Evaluation of the radiosensitizing potency of chemotherapeutic agents in
prostate cancer cells
Colin Rae and Robert J. Mairs
Radiation Oncology, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
ABSTRACT
Purpose: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are
low and treatment options are limited to chemotherapy and hormonal therapy. Although ionizing radi-
ation is used to treat localized and metastatic prostate cancer, the most efficient use of radiotherapy is
yet to be defined. Our purpose was to determine in vitro the potential benefit to be gained by com-
bining radiation treatment with cytotoxic drugs.
Materials and methods: Inhibitors of DNA repair and heat shock protein 90 and an inducer of oxida-
tive stress were evaluated in combination with X-radiation for their capacity to reduce clonogenic sur-
vival and delay the growth of multicellular tumor spheroids.
Results: Inhibitors of the PARP DNA repair pathway, olaparib and rucaparib, and the HSP90 inhibitor
17-DMAG, enhanced the clonogenic cell kill and spheroid growth delay induced by X-radiation.
However, the oxidative stress-inducing drug elesclomol failed to potentiate the effects of X-radiation.
PARP inhibitors arrested cells in the G2/M phase when administered as single agents or in combination
with radiation, whereas elesclomol and 17-DMAG did not affect radiation-induced cell cycle modulation.
Conclusion: These results indicate that radiotherapy of prostate cancer may be optimized by combin-
ation with inhibitors of PARP or HSP90, but not elesclomol.
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Introduction
While external beam radiotherapy is effective for local control
and palliation in prostate cancer patients, its use to treat
widespread disease is limited (Bonkhoff 2012). Furthermore,
intense local irradiation can result in damage to adjacent,
non-cancerous tissues, and wide-field radiotherapy is associ-
ated with bone marrow toxicity. In order to enhance radio-
therapy, there are several options for intervention, including
the application of agents directed against DNA repair path-
ways, redox homeostasis and pathways associated with
tumor cell survival (Mairs & Boyd 2011).
The activity of the DNA repair enzyme, poly(ADP-ribose)-
polymerase [PARP], is generally greater in cancer cells than in
normal cells (Zaremba et al. 2009). Inhibitors of PARP
improve the efficiency and selectivity of DNA-damaging
agents (Calabrese et al. 2004). The PARP inhibitors olaparib
and rucaparib have entered clinical trials for several cancer
types, either as monotherapy or in combination with cyto-
toxic drug therapy (Audeh et al. 2010; Tutt et al. 2010;
Plummer et al. 2013; Bendell et al. 2015; Mateo et al. 2015;
Drew et al. 2016). Radiosensitization has been demonstrated
in human and rodent cell lines and in experimental tumors
by treatment with PARP inhibitors (Virag & Szabo 2002; Brock
et al. 2004; Calabrese et al. 2004), indicating their potential
as components of combination therapy.
Ionizing radiation damages DNA directly or through the
production of reactive oxygen and nitrogen species (ROS and
RNS). These reactive molecules, particularly hydroxyl radical,
induce clustered DNA lesions and lethal double strand breaks
and can be derived from radiolysis of water, the mitochon-
drial electron transport chain or bystander effects. Cancer
cells produce ROS in abundance due to aberrant mitochon-
drial activity and unregulated metabolism (Trachootham
et al. 2009). Therefore, they are susceptible to treatments
that further disrupt the oxidant/antioxidant balance resulting
in an increase in ROS levels which may overwhelm antioxi-
dant capacity and initiate apoptosis (Storz 2005). In contrast,
normal cells are less sensitive to ROS generation because
their ROS content is lower and their antioxidative metabolism
is more efficient. The primary mechanism of action of the
drug elesclomol [N-malonyl-bis (N0-methyl-N0-thiobenzoylhy-
drazide)] is the generation of ROS leading to oxidative stress
which induces growth arrest and apoptosis in cancer, but
not normal, cells (Kirshner et al. 2000; Qu et al. 2009; Nagai
et al. 2012). In preclinical studies, elesclomol sensitized can-
cer cells to other chemotherapeutic agents (Qu et al. 2009;
Blackman et al. 2012) and, when combined with paclitaxel in
a phase II clinical trial, was shown to prolong progression-
free survival in patients with metastatic melanoma (O’Day
et al. 2009). Therefore, drug-induced increase in ROS is a
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potentially effective method to enhance the efficacy of
radiotherapy.
Due to the increased stress response in metabolically
hyperactive cancer cells, elevated levels of heat shock pro-
teins have been observed in many tumor types (Mahalingam
et al. 2009). Heat shock protein 90 (Hsp90) is a molecular
chaperone critical for the folding, assembly and activity of
multiple proteins. Its client proteins include signalling mole-
cules, such as nuclear hormone receptors and tyrosine kin-
ases (Lu et al. 2012), whose mutation or overexpression
promotes the growth and survival of tumor cells. Inhibition
of Hsp90 is a mechanism for inhibiting simultaneously mul-
tiple signaling pathways that promote cancer cell survival
and proliferation. Geldanamycin and its derivatives display
potent antitumor activity resulting from high affinity binding
to Hsp90 (Tian et al. 2004). One such drug is 17-allylamino-
demethoxygeldanamycin (17-AAG, tanespimycin), which is
less hepatotoxic than geldanamycin. Preclinical data indi-
cated that 17-AAG synergistically enhanced the cancer killing
activity of various cytotoxic agents (Lu et al. 2012). Therefore,
therapies which induce further cellular stress on tumor cells,
including ionizing radiation, are likely to enhance the effects
of Hsp90 inhibitors (Solit & Chiosis 2008). However, the clin-
ical use of 17-AAG has been hampered by poor solubility
and lack of oral bioavailability. The water-soluble geldanamy-
cin derivative 17-dimethylaminoethylamino-17-demethoxygel-
danamycin (17-DMAG, alvespimycin) appeared to overcome
these problems and exhibited antitumor activity in preclinical
models (Hollingshead et al. 2005). Significantly, 17-DMAG
sensitized human tumor cells to radiation both in vitro and in
vivo (Bull et al. 2004).
To determine the potential therapeutic benefit to be
gained from combined modality treatments, the antitumor
potencies of two PARP inhibitors, olaparib and rucaparib, ele-
sclomol and 17-DMAG were evaluated and compared in com-
bination with X-radiation in 2- and 3-dimensional in vitro
models of prostate cancer cell lines using as endpoints clono-
genic survival and growth delay of multicellular tumor
spheroids.
Materials and methods
Reagents
All cell culture media and supplements were purchased from
Life Technologies (Paisley, UK), unless stated otherwise.
Olaparib, rucaparib and elesclomol were purchased from
Selleckchem (Suffolk, UK). All other chemicals, including 17-
DMAG, were from Sigma-Aldrich (Dorset, UK). Stock solutions
of olaparib, 17-DMAG and elesclomol were prepared in
dimethyl sulfoxide (DMSO). The maximum DMSO concentra-
tion in culture medium was 0.1% (v/v).
Tissue culture
Human prostate cancer cell lines, PC3 and LNCaP, were
obtained from American Type Culture Collection (Manassas,
VA) and were used in this study for less than 6 months after
resuscitation. PC3 cells were maintained in F12K medium
supplemented with 10% (v/v) fetal bovine serum (Autogen
Bioclear, Wiltshire, UK), 2mM L-glutamine, 0.1mM sodium
pyruvate and 50 lg/ml gentamicin. LNCaP cells were main-
tained in RPMI 1640 medium supplemented with 10% (v/v)
fetal bovine serum (Hyclone, Fisher Scientific, UK), 1% (v/v)
HEPES, 1% (v/v) D-glucose, 1mM sodium pyruvate, 4mM L-
glutamine, 50 lg/ml gentamicin.
MTT cell proliferation assay
MTT reduction was performed according to the method of
Mosmann (1983). Cells were seeded in 96-well plates, and
incubated for 2 days to allow exponential phase growth.
Cells were then washed twice with PBS and medium contain-
ing drug at the required concentration was added. After 48 h,
MTT was added to a final concentration of 0.5mg/ml and
cultures were incubated for 2 h. Cells were then solubilized
with DMSO before measuring absorbance at 570 nm.
Clonogenic survival assay
PC3 cells were seeded in 25 cm2 flasks at 105 cells/flask.
When cultures were in exponential growth phase, medium
was removed and replaced with fresh medium containing
drug. Cells were irradiated using an X-Strahl RS225 X-ray irra-
diator at a dose rate of 1.6 Gy per min. Flasks were then incu-
bated for 24 h at 37 C in 5% CO2. After treatment, cells were
counted and seeded in triplicate Petri dishes for clonogenic
survival assay. Cells were incubated at 37 C in 5% CO2 for
10 days. Colonies were fixed in methanol, stained with crystal
violet solution and colonies of at least 50 cells were counted.
Multicellular spheroid growth assay
Multicellular tumor spheroids consisting of LNCaP cells were
obtained using the liquid overlay technique (Yuhas et al.
1977). Spheroids were initiated by inoculating cells into a
plastic flask coated with 1% (w/v) agar. After 3 days, aliquots
of spheroids were transferred to sterile plastic tubes and cen-
trifuged at 12 g for 3min. Thereafter, spheroids were irradi-
ated or re-suspended in serum-free culture medium
containing drug. After treatment, the spheroids were washed
twice and those of approximately 100 lm in diameter were
transferred individually into agar-coated wells of 24-well
plates. Individual spheroid growth was monitored twice per
week for 3 weeks using an inverted phase-contrast micro-
scope connected to an image acquisition system. Two per-
pendicular diameters, dmax and dmin, were measured using
image analysis software (ImageJ) and the volume, V (lm3),
was calculated using the formula: V ¼ p  dmax  dmin2/6
(Neshasteh-Riz et al. 1997). The area under the V/V0 versus
time curve (AUC) was calculated for individual spheroids
using trapezoidal approximation.
Cell cycle analysis
Following treatment for 6 or 24 h, LNCaP or PC3 cells were
trypsinized, then washed twice with PBS. Cells were fixed in
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 195
ice cold 70% (v/v) ethanol; then washed twice with PBS and
re-suspended in PBS containing propidium iodide (10 lg/ml)
and RNase A (200 lg/ml). Cells were stained for 30min before
flow cytometric analysis using a FACSCalibur (BD Biosciences,
Mountain View, CA).
Statistical analysis
Data are presented as means ± standard error of the mean
(SEM), with the number of independent repetitions provided
in the legend to each figure. Statistical significance was
determined using Student’s t-test. A p value <0.05 was con-
sidered to be statistically significant and <0.01 highly signifi-
cant. To test for differences in spheroid growth between
experimental therapy groups, the Kruskal-Wallis test was
used with post hoc testing by the Mann-Whitney U test with
Bonferroni correction. Analysis was carried out using SPSS
software.
Results
Drug-induced inhibition of proliferation
All drugs used in this study (olaparib, rucaparib, elesclomol,
17-DMAG) decreased the rate of proliferation of PC3 and
LNCaP cells in a concentration-dependent manner, as shown
in Figure 1. Rucaparib and elesclomol significantly inhibited
proliferation in both cell lines when administered at concen-
trations 50 lM, whereas olaparib significantly inhibited
proliferation only in LNCaP cells. 17-DMAG decreased prolifer-
ation at concentrations 50 nM.
Enhancement of radiation-induced clonogenic cell kill
The concentration-dependent effect of drugs administered as
single agents is shown in Supplementary Figure 1, available
online. As shown in Figure 2(A), administration of the PARP
inhibitor olaparib (1 and 3lM) simultaneously with X-radi-
ation increased the kill of PC3 clonogens induced by either
agent alone. The IC50 values obtained following the exposure
of PC3 cells to X-rays alone, or in the presence of 1 and 3 lM
olaparib were 1.92 ± 0.14, 1.25 ± 0.05 and 0.96 ± 0.08Gy,
respectively. The surviving fractions following radiation treat-
ment at a dose of 2 Gy (SF2) were 0.50 ± 0.08, 0.21 ± 0.01 and
0.12 ± 0.03 for 0, 1 and 3lM olaparib, respectively. These
observations indicate concentration-dependent radiosensiti-
zation by olaparib.
The alternative PARP inhibitor rucaparib caused a similar
degree of radiosensitization, as presented in Figure 2(B). The
IC50 values obtained following the exposure of PC3 cells to
X-rays alone, or in the presence of 1 or 3lM rucaparib were
1.81 ± 0.21, 1.41 ± 0.20 and 1.00 ± 0.04Gy, respectively. The
SF2 values were 0.45 ± 0.01, 0.26 ± 0.05 and 0.13 ± 0.02 for 0,
1 and 3 lM rucaparib, respectively. These observations indi-
cate concentration-dependent radiosensitization by rucaparib
with potency similar to that of olaparib.
Simultaneous administration of elesclomol with X-radi-
ation did not enhance the clonogenic cell kill achieved by
Figure 1. The proliferation of PC3 and LNCaP cells exposed to drugs at a range of concentrations for 48 h was assessed using MTT assay. Cells were exposed to
(A) olaparib, (B) rucaparib, (C) elesclomol or (D) 17-DMAG. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p< .05 and p< .01
compared to untreated controls. Data are means ± SEM; n¼ 4.
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either treatment alone, manifest as overlapping radiation sur-
vival curves in Figure 2(C). The IC50 values obtained following
the exposure of PC3 cells to X-rays alone, or in the presence
of 10 and 30 lM elesclomol were 1.69 ± 0.10, 1.63 ± 0.16 and
1.59 ± 0.08Gy, respectively. The SF2 values were 0.43 ± 0.04,
0.35 ± 0.06 and 0.36 ± 0.04 for 0, 10 and 30 lM elesclomol,
respectively. The lack of significant differences in IC50 and
SF2 values compared to radiation alone suggests that ele-
sclomol did not sensitize these cells to radiation.
Inhibition of Hsp90 by 17-DMAG enhanced the clonogenic
killing ability of X-radiation when administered simultan-
eously, as shown in Figure 2(D). The IC50 values obtained
following the exposure of PC3 cells to X-rays alone, or in
the presence of 5 and 10 nM 17-DMAG were 1.78 ± 0.05,
1.11 ± 0.06 and 1.10 ± 0.09 Gy, respectively. The SF2 values
were 0.53 ± 0.02, 0.22 ± 0.02 and 0.23 ± 0.02 for 0, 5 and
10 nM 17-DMAG, respectively. These observations indicate
the radiosensitizing activity of 17-DMAG.
Enhancement of radiation-induced spheroid growth
delay
As shown in Figure 3, radiation alone caused a reduction in
the growth of multicellular spheroids composed of LNCaP
cells, indicated by an area under the spheroid growth curve
(AUC) of 56.2 ± 4.3% of untreated control spheroids, reported
in Table 1. The ability of the chemotherapeutic agents to
enhance this spheroid growth delay was investigated using
simultaneously administered combinations.
The PARP inhibitors olaparib and rucaparib had no signifi-
cant effect on spheroid growth when administered at 30 lM,
whereas 100 lM caused a reduction in spheroid growth.
Although the radiation-induced decrease in spheroid growth
was not significantly enhanced by 30 lM olaparib, simultan-
eous administration of 100 lM olaparib with radiation
resulted in a significantly enhanced spheroid growth delay,
shown in Figure 3(A). Rucaparib (100 lM) also significantly
enhanced the growth delay induced by radiation treatment,
as can be seen in Figure 3(B). As shown in Figure 3(C) and
Table 1, although elesclomol inhibited spheroid growth
when administered as a single agent, the growth delay
resulting from radiation exposure was not significantly
enhanced by co-administration of elesclomol at either 30 or
100 lM. Administration of 17-DMAG to spheroids as a single
agent decreased their growth rate, as shown in Figure 3(D).
The growth delay effect of radiation alone was significantly
enhanced by combination with 25 nM 17-DMAG.
Drug-induced alteration of cell cycle distribution
The effects of X-radiation and drug treatment on cell cycle
progression was assessed in LNCaP and PC3 cells and are
reported in Figure 4. Radiation alone significantly increased
the proportion of LNCaP and PC3 cells in the G2/M phase of
the cell cycle 6 h after administration. The G2/M arrest was
reduced in PC3 cells 24 h after irradiation and in LNCaP cells
a significant decrease in cells in G2/M phase was accompa-
nied by an increase in G1 phase cells. Administration of drugs
Figure 2. The effect of drugs on radiation-induced clonogenic cell kill. Drugs were administered simultaneously with X-rays and 24 h later clonogenic assay was
carried out. PC3 cells were exposed to (A) 1 or 3lM olaparib, (B) 1 or 3lM rucaparib, (C) 10 or 30 lM elesclomol or (D) 5 or 10 nM 17-DMAG. p< .05 andp< .01 compared to X-rays alone. Data are means ± SEM; n¼ 3.
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for 6 h had no significant effect on cell cycle distribution.
Treatment with the PARP inhibitors olaparib or rucaparib for
24 h resulted in significant arrest in G2/M phase. Combination
of PARP inhibitor with X-radiation resulted in an increase in
LNCaP and PC3 cells in G2/M phase compared with radiation
alone.
In LNCaP cells, 30 lM elesclomol induced a significant
decrease in G2/M cells 24 h after administration. However, the
combination of elesclomol with radiation induced no further
decrease in G2/M arrest compared with radiation alone. In
PC3 cells, 30 lM elesclomol induced a small increase in G2/M
(p< .05). However, when PC3 cells were treated with a com-
bination of X-radiation and 30 lM elesclomol, no significant
difference in the proportion of G2/M cells was observed com-
pared to untreated cells or cells treated with radiation only.
17-DMAG induced no significant change in cell cycle distribu-
tion of LNCaP 24 h after administration, whereas a small
increase in G2/M was observed in PC3 cells. No alteration of
the radiation-induced effect was observed in either cell line
after simultaneous administration of 17-DMAG.
Discussion
We have assessed the ability of several classes of chemother-
apeutic agents to enhance the tumor-killing efficacy of radi-
ation, administered in the form of external beam X-rays. The
anti-proliferative activity of the drugs was evaluated as well
as their ability to decrease survival of clonogens and growth
of multicellular spheroids. In addition, the cell cycle distribu-
tion of cells after administration of drugs alone and in com-
bination with radiation was determined. Two prostate cell
lines were used in this study: PC3 cells which are androgen-
insensitive and form clonogens, but not multicellular sphe-
roids; and LNCaP cells which are androgen-sensitive and
Figure 3. The effect of radiation and drugs, alone or in combination, on the growth of LNCaP spheroids. Spheroids composed of LNCaP cells were exposed to
(A) 30 or 100lM olaparib, (B) 30 or 100 lM rucaparib, (C) 30 or 100 lM elesclomol or (D) 10 or 25 nM 17-DMAG, alone or in simultaneous combination with 2 Gy
X-radiation and 24 h later were transferred to agar-coated plates. Each spheroid was then photographed twice per week and change in spheroid volume (V/V0) was
measured up to 21 days. Data are means, n¼ 3. Error bars are omitted for clarity.
Table 1. Comparison of the effect of single-agent treat-
ment with combination treatment on the growth of
LNCaP spheroids. Data are expressed as area under the
volume-time curve (AUC). Values are means ± SEM of
three separate experiments.
Treatment AUC (% of control)
2 Gy X-ray 56.2 ± 4.3
30 lM olaparib 101.4 ± 10.6
2 Gy X-ray þ30 lM olaparib 53.3 ± 9.5
100 lM olaparib 76.5 ± 12.8
2 Gy X-ray þ100 lM olaparib 27.7 ± 12.3†
30 lM rucaparib 93.8 ± 8.5
2 Gy X-ray þ30 lM rucaparib 28.7 ± 5.0
100 lM rucaparib 72.3 ± 8.6
2 Gy X-ray þ100 lM rucaparib 28.4 ± 10.5†
30 lM elesclomol 88.8 ± 4.4
2 Gy X-ray þ30 lM elesclomol 45.5 ± 14.2
100 lM elesclomol 61.9 ± 13.1
2 Gy X-ray þ100 lM elesclomol 51.4 ± 8.7
10 nM 17-DMAG 75.9 ± 3.6
2 Gy X-ray þ10 nM 17-DMAG 44.2 ± 14.9
25 nM 17-DMAG 59.9 ± 13.9
2 Gy X-rays þ25 nM 17-DMAG 21.5 ± 5.4†
pertains to combinations compared with drug alone;
†pertains to combinations compared with X-radiation
alone; /† p< .05.
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form spheroids, but did not form clonogens in our hands.
The anti-proliferative and cell cycle modulating activity in
monolayer cultures of both cell lines did, however, allow
some comparisons to be made.
The radiosensitizing potential of drugs was assessed in
2- and 3-dimensional tumor models. The concentrations of
drugs required to significantly affect the proliferation and
clonogenic survival of monolayer cultures of both LNCaP
and PC3 cells were similar, whereas the concentration
required to induce significant delay of spheroid growth
were greater for all drugs used. Multicellular spheroids are
representative of micrometastases in their prevascular stage
of development. The relative resistance of multicellular
spheroids has previously been observed and is most likely
due to differences in drug penetration and the microenvir-
onment of the various layers within the spheroid (Kwok &
Twentyman 1985). The results observed here confirm that
the greater concentration required for growth delay and
radiosensitization of spheroids were not due to differences
in the cell response, but most likely due to the 3-dimen-
sional structure of spheroids.
It is possible that the combination of radiation with radio-
sensitizing drugs increased the induction of apoptosis, similar
to the radiosensitizing effect of the fatty acid inhibitor C75
(Rae et al. 2015). The response to drugs or radiation may also
be influenced by the p53 status of the cells. PC3 cells are
p53 non-functional, whereas LNCaP cells are p53 wild-type
(Carroll et al. 1993). As demonstrated here and previously
(Rae et al. 2015), the cell cycle distribution differs between
PC3 and LNCaP cells after irradiation. Cell cycle arrest in
G2/M phase was observed in both cell lines 6 h after
irradiation. In PC3 cells, the cell cycle distribution returns to
control proportions 24 h after irradiation, whereas LNCaP cells
accumulate in G1 phase. This may be explained by the ineffi-
ciency of DNA damage repair mechanisms reported in LNCaP
cells in G2/M phase (Xie et al. 2010) and consequent reliance
of G1 checkpoints, whereas PC3 cells lack the ability to arrest
in G1 phase.
DNA repair is a potential target pathway for tumors and
inhibitors of repair have been shown to be effective radio-
sensitizers (Brock et al. 2004). Tumors with aberrant DNA
repair pathways are particularly sensitive to PARP inhibitors
(Farmer et al. 2005; Horton et al. 2014) and olaparib is
approved by the FDA for the treatment of patients whose
ovarian cancers harbour BRCA mutations. Furthermore, ola-
parib led to a high response rate in prostate cancer patients
with metastatic, castrate-resistant disease characterized by
defects in DNA-repair genes (Mateo et al. 2015), suggesting
that PARP inhibitors would be a particularly useful addition
to the treatment of this cancer.
PARP binds to both single- and double-stranded DNA
breaks, partly via the base excision pathway, which plays an
important role in repairing single-strand breaks induced by
ionizing radiation (Chalmers 2009). Therefore, it is likely that
PARP inhibition promotes increased formation of DNA single-
strand breaks by ionizing radiation, which are subsequently
converted to potentially lethal double-strand breaks during
cell replication. Rucaparib has been used as a radiosensitizer
in phase I and II clinical trials in head and neck cancers and
CNS neoplasm (Verheij et al. 2010; Mangerich & Burkle 2011),
indicating its potential in the clinical management of other
solid tumours.
Figure 4. (A) Cell cycle distribution of LNCaP and PC3 cells 6 and 24 h after 2 Gy X-irradiation. LNCaP and PC3 cells in G2/M phase of the cell cycle 24 h after expos-
ure to (B) 1 or 3lM olaparib, (C) 1 or 3 lM rucaparib, (D) 10 or 30 lM elesclomol and (E) 5 or 10 nM 17-DMAG. Data are means ± SEM; n¼ 3. p< .05 and p< .01
compared to untreated contol cells. †p< .05 and ††p< .01 compared to radiation treatment alone.
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Here, we show that both PARP inhibitors, olaparib and
rucaparib, had an anti-proliferative effect in both LNCaP and
PC3 cells at similar concentrations when cultured as mono-
layers, with rucaparib being the more potent drug. Crucially,
radiosensitization was demonstrated in both LNCaP (andro-
gen-sensitive) and PC3 (androgen-insensitive) cell lines, sug-
gesting that androgen sensitivity did not affect their activity.
Furthermore, olaparib and rucaparib increased the proportion
of cells in G2/M phase of the cell cycle in both LNCaP (p53
wild type) and PC3 (p53 non-functional) cell lines, suggesting
that p53 status was not a determining factor in their activity.
Olaparib and rucaparib enhanced the clonogenic cell killing
and spheroid growth delay activity of radiation and accord-
ingly, these PARP inhibitors can be considered as sensitizers
of prostate cancer cells to radiation.
The lethality of ionizing radiation and some chemothera-
peutic agents is hypothesized to be due to increasing ROS
concentrations to cytotoxic levels preferentially in tumors
which typically have elevated levels of ROS and impaired
antioxidant activity as a consequence of higher rates of pro-
liferation and metabolism (Trachootham et al. 2009). The sen-
sitivity of cancer cells to therapeutic schemes which
stimulate cell death through ROS production encourages the
use of these drugs in combination with radiotherapy.
Clinical trials using elesclomol have primarily assessed its
efficacy in melanoma patients. Due to melanin biosynthesis,
melanoma cells contain particularly high levels of ROS
(Wittgen & van Kempen 2007), and this may result in this can-
cer being sensitive to elesclomol-induced cytotoxicity.
Advanced prostate cancer is also associated with a state of
high oxidative stress (Yossepowitch et al. 2007), suggesting
that the prostate cancer cell lines used in this study would be
similarly sensitive to elesclomol. A phase I/II study of elesclo-
mol plus docetaxel in patients with metastatic castration
refractory prostate cancer has recently been completed
(NCT00808418), although the findings are currently unknown.
The encouraging results of a phase II clinical trial of elesclomol
in combination with paclitaxel (O’Day et al. 2009) were not
confirmed in a subsequent phase III trial (O’Day et al. 2013).
However, it is possible that a population of patients with nor-
mal serum lactate dehydrogenase (LDH) levels may respond
well to this therapy, whereas high LDH levels may predict a
negative clinical effect (Nagai et al. 2012; O’Day et al. 2013),
reflecting the importance of tumor mitochondrial activity.
Concentrations of elesclomol used in this study were suffi-
cient to decrease proliferation, clonogenic survival and spher-
oid growth. Although the degree of ROS generation was
reported to be higher in PC3 cells than in LNCaP cells
(Kumar et al. 2008), we demonstrate here that, when admin-
istered to monolayer cultures as a single agent, elesclomol
affected both cell lines similarly, with growth inhibition and
redistribution of the cells cycle observed in response to simi-
lar concentrations of elesclomol. Although oxidative stress
can directly activate p53 pro-apoptotic signalling, the cyto-
toxic effect of elesclomol was similar in PC3 and LNCaP cells,
suggesting that p53 does not play a major role in the
observed effects of elesclomol. Radiation induced an accumu-
lation of LNCaP cells in the G1 phase of the cell cycle 24 h
after administration, which was similar to the effect of
elesclomol, and this was not increased by combination treat-
ment. In addition, combination with radiation enhanced nei-
ther the radiation-induced clonogenic kill of PC3 cells nor the
decreased growth of LNCaP spheroids, confirming that ele-
sclomol did not sensitize these cell lines to X-radiation.
Elesclomol is most active in well-oxygenated cells,
whereas hypoxia is likely to reduce activity (O’Day et al.
2013). Although LNCaP spheroids contain a hypoxic core of
cells, this occurs only in spheroids 300 lm in diameter
(Ballangrad et al. 1999). We have recently demonstrated the
absence of hypoxic regions in newly-initiated spheroids
(<100 lm diameter) (Tesson et al. 2016). When administered
as a single agent at a concentration of 100lM, elesclomol
inhibited spheroid growth. However, no radiosensitization
was observed in response to this concentration of elesclomol.
Furthermore, no enhancement of radiation-induced clono-
genic cell kill was observed following the treatment of
2-dimensional cultures with elesclomol at concentrations
which, as a single agent, decreased clonogenic survival. This
suggests that the observed lack of radiosensitization by ele-
sclomol was unlikely to be a result of the development of a
hypoxic core in the spheroids.
As both radiation and elesclomol can interact with the
electron transport chain (ETC) to elevate intracellular ROS lev-
els (Blackman et al. 2012; Yamamori et al. 2012), it is possible
that radiation-induced ROS generation is sufficient for lethal
DNA damage to occur and that further increasing oxidative
stress by co-administration of elesclomol offers no additional
cell killing effect. Combinations of elesclomol with drugs
which inhibit the ETC complex synergistically enhanced the
cytotoxic effects of elesclomol (Blackman et al. 2012),
whereas ETC function was upregulated by ionizing radiation
(Yamamori et al. 2012). This may explain the lack of enhance-
ment of single modality treatment which was observed in
this study and suggests that combination of treatments
which act through a shared mechanism of action may not be
an effective method for sensitizing tumors to radiotherapy.
Elevated Hsp90 expression in many solid and hematologic
tumors correlates with poor prognosis (Den and Lu 2012).
Hsp90 promotes tumor growth and survival by chaperoning
factors such as HER2 proto-oncogene and molecules such as
Akt (involved in cell survival, inhibiting apoptosis), c-Src (pro-
motes tumor growth and survival) and Raf-1 (promotes cell
division via MAPK/Erk pathway) (Soo et al. 2008). Hsp90 is
also implicated in tumor invasion and metastasis through its
interaction with H1F1a, VEGF and MMP-2 (Soo et al. 2008).
Previous in vitro studies have indicated that the Hsp90
inhibitor 17-DMAG enhanced radiation-induced kill of cells
from a variety of tumors (Bull et al. 2004; Dote et al. 2006; Koll
et al. 2008). In agreement with previous reports of the efficacy
of treatment with 17-AAG and 17-DMAG of prostate cancer
clonogens and spheroids (Enmon et al. 2003; Bull et al. 2004),
we have demonstrated here that 17-DMAG sensitized prostate
cancer cell lines to radiation in both 2- and 3-dimensional
models in a supra-additive manner. We observed that the con-
centration of 17-DMAG required to enhance the growth delay
of LNCaP spheroids was 10 nM. This was significantly lower
than the previously reported concentration of 17-AAG
(1000 nM) required for synergism with 2Gy radiation
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(Enmon et al. 2003), suggesting that 17-DMAG is a more potent
radiosensitizer than 17-AAG. Crucially, the concentration of
17-DMAG, as a single agent, required for radiosensitization, had
negligible cytotoxicity, indicating that therapeutic enhance-
ment would be possible with minimal increase in toxicity.
The radiosensitizing effect of Hsp90 inhibition may be
caused by modulation of the activity of proteins associated
with radioresistance, including Raf-1, ErbB2 and Akt (Russell
et al. 2003), leading to alterations in DNA repair ability,
diminished NF-jB activity, cell cycle regulation and apoptosis
(Dote et al. 2006; Koll et al. 2008). The p53 status of cells has
been suggested to play only a minor role in radiosensitiza-
tion by 17-DMAG (Koll et al. 2008), and this was confirmed
by the radiosensitizing effect observed here in both PC3 cells
and LNCaP cells. Radiosensitization induced by the Hsp90
inhibitor radicicol in prostate cancer cells has been ascribed
to degradation of the androgen receptor, which is an Hsp90
client (Harashima et al. 2005). However, we have shown here
a radiosensitizing effect in both androgen-sensitive (LNCaP)
and androgen-insensitive (PC3) cell lines, suggesting that
17-DMAG may be clinically useful even during progression of
hormone-refractory disease.
Clinical activity of Hsp90 inhibitors has been demonstrated
primarily in tumors with known alterations in oncoproteins
which are Hsp90 client proteins, such as amplified HER2 in
breast cancer, ALK rearrangements in non-small cell lung can-
cer and mutant BRAF in melanoma (Solit & Chiosis 2008; Butler
et al. 2015). Therefore, as with PARP inhibitors, it is likely that
the major clinical impact will be obtained in stratified patient
groups selected for known biomarkers indicating sensitivity to
these agents. A phase I trial of 17-DMAG for advanced solid
tumors revealed clinical activity in several tumor types includ-
ing a complete response in hormone-refractory prostate can-
cer (Pacey et al. 2011). However, in general, clinical activity of
Hsp90 inhibitors as single agents has been modest and it is
predicted that the maximum clinical benefit from these agents
are likely to be in combination therapies.
This preliminary screening study indicates that it is pos-
sible to sensitize prostate cancer cells to radiation using
pharmacological inhibitors of DNA repair and stress response
proteins, and efforts concentrating on these pathways are
likely to lead to improvements in the efficacy of radiotherapy.
Although the radiosensitizing potential of PARP inhibitors has
been suggested previously, this study compares for the first
time two alternative PARP inhibitors currently in clinical trials.
The ability of elesclomol to potentiate radiation-induced
cancer killing has also not been previously evaluated. In add-
ition, the inclusion of the radiosensitizing Hsp90 inhibitor
17-DMAG in this study allows direct comparison of the
potency and mode of action with respect to cell cycle modu-
lation. Further investigation in vivo of the efficacy of the
radiosensitizing agents in combination with radiotherapy
may expedite progress of this therapeutic strategy for the
clinical management of metastatic prostate cancer.
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